Ketamine patient-controlled analgesia for dysesthetic central pain

Steven Cohen, M. DeJesus

Research output: Contribution to journalArticle

Abstract

Study Design: Case report. Objectives: To describe the first use of intravenous (IV) ketamine as the sole agent in a patient-controlled analgesic delivery system (ie PCA) in a patient with cervical syringomyelia. Setting: A tertiary-care university teaching hospital in New York City. Methods: A 41-year-old tetraplegic female on high-dose opioids suffering from intractable dysesthetic central pain received her best pain relief from a low-dose ketamine infusion after failing trials with multiple neuropathic medications. After several weeks of titrating her infusion rate up and down, she was switched to an IV ketamine PCA device. Results: The patient was maintained on an IV ketamine PCA for almost 1 year under the following settings: 2.7 mg/h basal rate; 2.7 mg/h demand dose; 15 min lockout period. Although she continues to report some pain, it has dramatically decreased since the ketamine PCA was instituted, enabling us to significantly reduce her opioid dosage. Conclusions: Ketamine PCA may be a viable treatment option in patients suffering from intractable central pain. The rationale for this treatment, along with dosing guidelines and possible drawbacks, is discussed.

Original languageEnglish (US)
Pages (from-to)425-428
Number of pages4
JournalSpinal Cord
Volume42
Issue number7
DOIs
StatePublished - Jul 2004
Externally publishedYes

Fingerprint

Patient-Controlled Analgesia
Ketamine
Passive Cutaneous Anaphylaxis
Pain
Opioid Analgesics
Syringomyelia
Intractable Pain
Tertiary Healthcare
Teaching Hospitals
Analgesics
Guidelines
Equipment and Supplies
Therapeutics

Keywords

  • Ketamine
  • N-methyl-D-aspartate
  • Patient-controlled analgesia
  • Spinal cord injury
  • Syringomyelia

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Ketamine patient-controlled analgesia for dysesthetic central pain. / Cohen, Steven; DeJesus, M.

In: Spinal Cord, Vol. 42, No. 7, 07.2004, p. 425-428.

Research output: Contribution to journalArticle

Cohen, Steven ; DeJesus, M. / Ketamine patient-controlled analgesia for dysesthetic central pain. In: Spinal Cord. 2004 ; Vol. 42, No. 7. pp. 425-428.
@article{bbdc272d6cfc42f1b88b39c16c02d040,
title = "Ketamine patient-controlled analgesia for dysesthetic central pain",
abstract = "Study Design: Case report. Objectives: To describe the first use of intravenous (IV) ketamine as the sole agent in a patient-controlled analgesic delivery system (ie PCA) in a patient with cervical syringomyelia. Setting: A tertiary-care university teaching hospital in New York City. Methods: A 41-year-old tetraplegic female on high-dose opioids suffering from intractable dysesthetic central pain received her best pain relief from a low-dose ketamine infusion after failing trials with multiple neuropathic medications. After several weeks of titrating her infusion rate up and down, she was switched to an IV ketamine PCA device. Results: The patient was maintained on an IV ketamine PCA for almost 1 year under the following settings: 2.7 mg/h basal rate; 2.7 mg/h demand dose; 15 min lockout period. Although she continues to report some pain, it has dramatically decreased since the ketamine PCA was instituted, enabling us to significantly reduce her opioid dosage. Conclusions: Ketamine PCA may be a viable treatment option in patients suffering from intractable central pain. The rationale for this treatment, along with dosing guidelines and possible drawbacks, is discussed.",
keywords = "Ketamine, N-methyl-D-aspartate, Patient-controlled analgesia, Spinal cord injury, Syringomyelia",
author = "Steven Cohen and M. DeJesus",
year = "2004",
month = "7",
doi = "10.1038/sj.sc.3101599",
language = "English (US)",
volume = "42",
pages = "425--428",
journal = "Spinal Cord",
issn = "1362-4393",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Ketamine patient-controlled analgesia for dysesthetic central pain

AU - Cohen, Steven

AU - DeJesus, M.

PY - 2004/7

Y1 - 2004/7

N2 - Study Design: Case report. Objectives: To describe the first use of intravenous (IV) ketamine as the sole agent in a patient-controlled analgesic delivery system (ie PCA) in a patient with cervical syringomyelia. Setting: A tertiary-care university teaching hospital in New York City. Methods: A 41-year-old tetraplegic female on high-dose opioids suffering from intractable dysesthetic central pain received her best pain relief from a low-dose ketamine infusion after failing trials with multiple neuropathic medications. After several weeks of titrating her infusion rate up and down, she was switched to an IV ketamine PCA device. Results: The patient was maintained on an IV ketamine PCA for almost 1 year under the following settings: 2.7 mg/h basal rate; 2.7 mg/h demand dose; 15 min lockout period. Although she continues to report some pain, it has dramatically decreased since the ketamine PCA was instituted, enabling us to significantly reduce her opioid dosage. Conclusions: Ketamine PCA may be a viable treatment option in patients suffering from intractable central pain. The rationale for this treatment, along with dosing guidelines and possible drawbacks, is discussed.

AB - Study Design: Case report. Objectives: To describe the first use of intravenous (IV) ketamine as the sole agent in a patient-controlled analgesic delivery system (ie PCA) in a patient with cervical syringomyelia. Setting: A tertiary-care university teaching hospital in New York City. Methods: A 41-year-old tetraplegic female on high-dose opioids suffering from intractable dysesthetic central pain received her best pain relief from a low-dose ketamine infusion after failing trials with multiple neuropathic medications. After several weeks of titrating her infusion rate up and down, she was switched to an IV ketamine PCA device. Results: The patient was maintained on an IV ketamine PCA for almost 1 year under the following settings: 2.7 mg/h basal rate; 2.7 mg/h demand dose; 15 min lockout period. Although she continues to report some pain, it has dramatically decreased since the ketamine PCA was instituted, enabling us to significantly reduce her opioid dosage. Conclusions: Ketamine PCA may be a viable treatment option in patients suffering from intractable central pain. The rationale for this treatment, along with dosing guidelines and possible drawbacks, is discussed.

KW - Ketamine

KW - N-methyl-D-aspartate

KW - Patient-controlled analgesia

KW - Spinal cord injury

KW - Syringomyelia

UR - http://www.scopus.com/inward/record.url?scp=3242791580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242791580&partnerID=8YFLogxK

U2 - 10.1038/sj.sc.3101599

DO - 10.1038/sj.sc.3101599

M3 - Article

C2 - 15007375

AN - SCOPUS:3242791580

VL - 42

SP - 425

EP - 428

JO - Spinal Cord

JF - Spinal Cord

SN - 1362-4393

IS - 7

ER -